Aligos Therapeutics(ALGS) - 2025 Q4 - Annual Results

Financial Performance - Aligos reported a net loss of $19.9 million for Q4 2025, a significant reduction from a net loss of $82.2 million in Q4 2024, resulting in a basic and diluted net loss per share of $(1.91) compared to $(13.08) in the prior year[9][22]. - For the full year 2025, the net loss was $24.2 million, down from $131.2 million in 2024, with a basic and diluted net loss per share of $(2.45) versus $(20.94) in 2024[10][22]. Cash and Investments - Cash, cash equivalents, and investments totaled $77.8 million as of December 31, 2025, an increase from $56.9 million at the end of 2024, expected to fund operations into Q3 2026[8][25]. Research and Development Expenses - Research and development (R&D) expenses for Q4 2025 were $17.0 million, slightly up from $16.0 million in Q4 2024, primarily due to increased costs for the pevifoscorvir sodium Phase 2 clinical trial[11][22]. - Total R&D expenses for the year 2025 were $69.5 million, a decrease from $70.3 million in 2024, attributed to increased government funding for the coronavirus program[12][22]. General and Administrative Expenses - General and administrative (G&A) expenses for Q4 2025 were $4.9 million, down from $5.2 million in Q4 2024, mainly due to reduced legal and related expenses[13][22]. Clinical Trials and Studies - The Phase 2 B-SUPREME study of pevifoscorvir sodium completed enrollment of 60 HBeAg- participants in January 2026, with interim analyses expected in 2026[5][2]. - Aligos is advancing ALG-170675 into IND-enabling studies in partnership with Xiamen Amoytop Biotech, with development costs in China funded by Amoytop[2][5]. Product Development and Commercialization - The combination therapy of ALG-055009 with incretin receptor agonists showed a maximum body weight loss of 39% compared to monotherapy, indicating potential for significant weight loss benefits[17][4]. - The company appointed James Hassard as Executive Vice President, Chief Commercial Officer, to enhance its global commercial capabilities[7][22].